Epsilon Healthcare Limited · ASX:EPN
Epsilon Healthcare — Investor Presentation (September 2019)
18 slides from Epsilon Healthcare's investor presentation, Sep 24, 2019
Slide 1: THC Global Group Corporate Presentation September 2019
THC GLOBAL GROUP (ASX: THC) Corporate Presentation | September 2019
Slide 2: A Vertically Integrated Global Cannabis Company
THC Global Group Limited (ASX:THC) A Vertically Integrated Global Cannabis Company A Farm-to-Pharma business model focused on delivering low cost, high quality cannabis to both patients and the global cannabis export market 2
Slide 3: Farm to Pharma Vertical Integration
FARM TO PHARMA VERTICAL INTEGRATION RESEARCH & CANNABIS PHARMA GMP EXPORT & DEVELOPMENT CULTIVATION MANUFACTURE PATIENTS Proprietary Cannabis Low-cost cannabis Pharma-grade GMP Supply of finished Sativa strains and cultivation in Australia certified API isolates, product to patients and ‘Next-Genera
Slide 4: Australian Cannabis Facilities
AUSTRALIAN CANNABIS FACILITIES ‘EDEN FARMS’ ‘BUNDY’ ‘BALLINA’ ‘SOUTHPORT’ CULTIVATION CULTIVATION CULTIVATION MANUFACTURE 66,000m 2 of operational hydroponics Farm-to-Pharma cannabis operation 73,500m 2 USDA Certified Organic Pharma grade GMP manufacture of greenhouses with adjacent 180,000m 2 with
Slide 5: 'Eden Farms' Cultivation
'EDEN FARMS’ CULTIVATION An operational hydroponics cultivation facility with scalability to support the rapid increase in production at THC Global’s Manufacturing Facility SCALABLE OPERATION 66,000m2 of hydroponic greenhouses and 180,000m2 of agricultural land for open-field cultivation at signific
Slide 6: 'Bundy' Cultivation
‘BUNDY’ CULTIVATION Fully Licenced for Farm to Pharma Production – research, cultivation and manufacturing capabilities all on site with tissue culturing facility to support other cultivation projects using proprietary strains FARM TO PHARMA Cultivation already underway with existing research, culti
Slide 7: 'Ballina' Cultivation
‘BALLINA’ CULTIVATION Additional large scale cultivation project for plant material expansion capacity SECURED PROJECT 73,500m2 agricultural land in Northern NSW secured to establish a large scale cannabis cultivation site with up to 40,000m2 of greenhouses. Project to be commenced as internal deman
Slide 8: Pharma-Grade GMP Manufacturing Facility
EXPORT SCALE CAPACITY Capacity to support the entire near term Australian patient demand and be a global exporter commencing early 2020 Above: The Australian Federal Minister for Health, The Hon. Greg Hunt (centre), accompanied by Angie Bell MP , the Federal Member for Moncrieff (L) and Rob Molhoek
Slide 9: Initial Medicines Range
INITIAL MEDICINES RANGE All products to be Australian Register of Therapeutic Goods (ARTG) listed enabling global exports CANNDEO CANNDEO CANNDEO THC RANGE THC|CBD RANGE CBD RANGE Targeted Targeted Available in availability in availability in early 2020 Mid 2020 Mid 2020 Product design and final spe
Slide 10: Extended Medicines Range
EXTENDED MEDICINES RANGE Expecting to launch extended range through 2020-21 for the domestic and global export markets All products to be Australian Register of Therapeutic Goods (ARTG) listed enabling global exports DRIED FLOWER GEL CAPSULES GEL-TABS TOPICALS Product design and final specifications
Slide 11: Medicinal Cannabis Revenue Timeline
MEDICINAL CANNABIS REVENUE TIMELINE Timeline to revenue from THC Global’s Australian Medicinal Cannabis production assets First full spectrum oil ARTG listings completed produced at to enable export from Manufacturing Facility Australia Nov 2019 Feb 2020 Jun 2020 Dec 2019 Apr 2020 Completion of GMP
Slide 12: Australian Cannabis Market
AUSTRALIAN CANNABIS MARKET A rapidly growing market with significant regulatory barriers for patient access and competition entry HIGH COST IMPORTS The Australian patient demand is currently supported THC Global Group almost entirely by high-cost imported product. Australian Operations THC Global ex
Slide 13: Global Market Potential
GLOBAL MARKET POTENTIAL Low cost high quality scalable production enabling THC Global to be globally competitive GLOBALLY COMPETITIVE Low cost production whilst meeting or exceeding the European standards and other quality expectations at scale, enables THC Global to compete with Aurora, Tilray, Can
Slide 14: Canadian Operations
CANADIAN OPERATIONS A diversified business group with a unique strategy targeted for the Canadian market HYDROPONICS EQUIPMENT CANNABIS OPERATIONS THC Global’s Crystal Mountain is a hydroponics Secured an 11 acre property in Nova Scotia, Canada equipment wholesale supplier into the global with a Let
Slide 15: THC Global Board
THC GLOBAL BOARD STEVEN XU ALAN BEASLEY CHAIRMAN DEPUTY CHAIRMAN Chartered accountant with over 15 years Over 30 years experience in investment experience. Significant past experience in banking and management. Former roles financing, IPO’s and M&A within sectors include Managing Director Goldman Sa
Slide 16: THC Global Executive Team
THC GLOBAL EXECUTIVE TEAM KEN CHARTERIS LAURA HARVEY JARROD WHITE Chief Executive Officer Chief Operating Officer Chief Financial Officer (Global) (Canada) (Global) ANDREW BEEHAG ELSIE GREEN MICHAEL HARRISON Medicinal Cannabis Compliance Officer API Manager (Asia Pacific) (Australia) (Australia) 16
Slide 17: Disclaimer
DISCLAIMER The material in this presentation (Material) is not and does not constitute an offer, Statements contained in this Material, particularly those regarding possible or invitation or recommendation to subscribe for, or purchase any security in THC assumed future performance, costs, dividends
Slide 18: Contact THC Global Group
CORPORATE OFFICE S ui t e 4 1 0 2 Le v e l 4 1 Aus t r al i a S q uar e 2 6 4 - 2 78 Geo r ge S t r eet CONTACT S y d n ey NS W 2 0 0 0 THC GLOBAL Aus t r al i a EMAIL GROUP c o r p o r at e@t h c . gl o b al ASX:THC WEB t h c . gl o b al 18
Epsilon Healthcare — Investor Presentation (September 2019) on 6ix